US Markets
Home›US Markets›Equities›AbbVie golden cross strengthens as Baxter dividend is…
AbbVie golden cross strengthens as Baxter dividend is eliminated
AbbVie declared a $1.73 quarterly dividend for an Aug. 14 payout, while Baxter cut its quarterly dividend to $0.01 after a -$900 million net income in FY2025.
Both AbbVie and Baxter International recently generated the same technical signal, a golden cross, when the 50-day moving average moved above the 200-day. But fundamentals are diverging sharply, with AbbVie’s outlook focused on dividend support and Baxter’s marked by a withdrawn income profile, according to Yahoo Finance.
For AbbVie, the golden cross formed around July 7 appears clean and is widening, with the 50-day at 222.91 versus a 200-day of 222.66, and both lines rising. The company also declared a $1.73 quarterly dividend, with an ex-dividend date of July 15 and a payment date of August 14, 2026, annualizing to $6.92 and implying a dividend yield near 2.8% at a $244.78 share price.
Baxter’s golden cross looks less convincing, with the 50-day at 19.85 only fractionally above the 200-day at 19.26, while the 200-day average is still declining. More importantly for retirees, Baxter eliminated its dividend after cutting the quarterly payout to $0.01, annualizing to $0.04 per share, and posted -$900 million net income in FY2025.
Yahoo Finance also noted that golden crosses are lagging momentum indicators and do not, by themselves, speak to cash flow or dividend safety, so the income-focused decision hinges on each company’s dividend fundamentals. Separately, the piece said AbbVie’s pipeline growth helped drive a raised full-year guidance, while it referenced SkyRizi and Rinvoq growth in Q1 2026.